Poststroke cognitive impairments and their therapy with ceraxon
https://doi.org/10.14412/2074-2711-2011-168
Abstract
Objective: to evaluate the effect of citicoline (ceraxon) on recovery of cognitive functions in patients after ischemic stroke.
Subjects and methods. Thirty-three patients (13 males and 20 women) aged 46-82 years (mean age 66.5±6.75 years) after ischemic stroke were examined 3 months to 1 year after its development. Neuropsychological examination showed that all the patients had mild or moderate cognitive impairments as disorders of memory, attention, and thinking.
Results and discussion. Ten-day treatment with citicoline (ceraxon) in a dose of 500 or 1000 mg/day caused positive changes in the neurody-namic characteristics of cognitive functions, and improvements in memory, thinking, and health in the patients. Cognitive improvement was more significant when ceraxon was used in a dose of 1000 mg/day.
Subjects and methods. Thirty-three patients (13 males and 20 women) aged 46-82 years (mean age 66.5±6.75 years) after ischemic stroke were examined 3 months to 1 year after its development. Neuropsychological examination showed that all the patients had mild or moderate cognitive impairments as disorders of memory, attention, and thinking.
Results and discussion. Ten-day treatment with citicoline (ceraxon) in a dose of 500 or 1000 mg/day caused positive changes in the neurody-namic characteristics of cognitive functions, and improvements in memory, thinking, and health in the patients. Cognitive improvement was more significant when ceraxon was used in a dose of 1000 mg/day.
About the Authors
N. V. Shakhparonova
Neurology Research Center, Russian Academy of Medical Sciences
Russian Federation
Moscow
Russian Federation
Moscow
A. S. Kadykov
Neurology Research Center, Russian Academy of Medical Sciences
Russian Federation
Moscow
Russian Federation
Moscow
E. M. Kashina
Neurology Research Center, Russian Academy of Medical Sciences
Russian Federation
Moscow
Russian Federation
Moscow
References
1. <div><p>Бойко А.Н., Батышева Т.Т., Багирь Л.В. и др. Опыт амбулаторного применения препарата церепро при ишемическом инсульте в раннем восстановительном периоде. Журн невропат и психиатр 2007;107(10):34-40.</p><p>Дамулин И.В. Дифференциальная диагностика и терапия деменций. Consilium medicum 2003;5(12):721-6.</p><p>Парфенов В.А., Вахнина Н.В., Никитина Л.Ю. Лечение постинсультных когнитивных нарушений. РМЖ 2010;18:16.</p><p>Hershey L. Dementia associated with stroke. Stroke 1989;21(Suppl. 9):12-3.</p><p>Pasquier F., Leys D. Why are stroke patients prone to develop dementia? J Neurol 1997;244:135-42.</p><p>Patel M., Coshall C., Rudd A. et al. Natural history of cognitive impairmentafter stroke and factors associated with its recovery. Cerebrovasc Dis 2001;1(Suppl. 4):9.</p><p>Desmond D.W., Morony J.T., Raik M.C. et al. Freguency and clinical determinatts of dementia after scchemic stroke. Neurology 2000;54:1124-31.</p><p>Voisin T., de Feneyrols R.A., le Traon P.A. et al. Cognitive impairment after first lacunar stroke: clinical features and risk factors. Cerebrovasc Dis 2002;13(Suppl. 3):69.</p><p>Roman G.C. Facts, myths, and controversies in vascular dementia. J Neurol Sci 2004;226:49-52.</p><p>oeLb C., Gandolfo C., Croce R. et al. Dementia associated with lacunar infarction. Stroke 1992;23(9):1225-9.</p><p>Baron J.C., Levasseur M., Mazoyer B. et al. Thalamo-cortical diaschisis: positron emission tomography in humans. J Neurol Neurosurg Psychiat 1992;55:935-42.</p><p>Gustafson L., Passant U. Clinical pathological correlates. In: Cerebrovascular Disease, Cognitive Impairment and Dementia. J.O. Brien et al. (eds). London, New York: Martin Dunitz, 2004;197-210.</p><p>Reilly M., Connolly S., Stack J. et al. Bilateral paramedian thalamic infarction: adistict but poorly recognized stroke syndrome. Q J Med 1992;297:63-70.</p><p>Mielke R., Kessler J., Szelies B. et al. Vascular demencia: perfusional and metabolic disturbances and effects therapy. J Neurol Transm 1996;47(Suppl. 1):183-91.</p><p>Saver J.L. Цитиколин: новые сведения о перспективном лекарственном средстве, осуществляющем нейропротекцию и нейрорепарацию. Международн неврол журн 2010;1(31):108-17.</p><p>Афанасьев В.В. Клиническое применение цитиколина и его роль в гемостазе клеточных мембран нейронов и органов эффекторов. Трудн пациент 2009;7(11):26-32.</p><p>Андреева Г.Н., Рождественский А.С., Маркелова М.В. и др. Клиническая эффективность использования цераксона в острейшем периоде ишемического инсульта. Леч заб ЦНС 2010;2:29-31.</p><p>Tanaka Y., Minematsu K., Hirano T. et al. Effects of CDP-choline on dynamic changes in LCBF and cognitive function in demented sub-jecte-PET study. Rinsho Shinkeigaku 1994;34:877-81.</p><p>Левин О.С. Применение цитиколина в лечении инсульта. РМЖ 2008;26:1772-6.</p><p>Левин О.С., Дударова М.А., Усольцева Н.И. Диагностика и лечение постинсультных когнитивных нарушений. Consilium medicum 2010;12(2):5-12.</p><p>Скворцова В.И., Бойцова А. Нейропротективная терапия в остром периоде церебрального инсульта. Врач 2007;12:25-8.</p><p>Eberhardt R., Dehrr I. Eficacia y tolerancia de CDP-colina en pacientes geriatricos con insuficiencia cerebral senile. Rev Esp Geriatr Gerontol 1989;24(Suppl.1):73-81.</p><p>Fioravanti M., Buckley A.E., Agnoli A. Citicoline in CCVD patients: Preliminary results of a multicenter study. Cerebral Pathology in Old Age: Neuroradiological and Neurophysiological Correlation. Pavia, 1982</p></div><br />
Review
For citations:
Shakhparonova NV, Kadykov AS, Kashina EM. Poststroke cognitive impairments and their therapy with ceraxon. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(3):56-60. (In Russ.) https://doi.org/10.14412/2074-2711-2011-168
Views:
1178
Email this article 